Zydus Lifesciences Q2 Review: A Mixed Bag for Investors Zydus Lifesciences Ltd. recently announced its Q2 FY26 results, which were a mixed bag for investors. While the company’s revenue beat estimates, its margins were subdued due to the lower revenue of gRevlimid and the impact of recent acquisitions in the consumer wellness and medtech divisions. […]
Harsha Engineers Shares Upgraded To ‘Buy’ By IDBI Capital: A Positive Outlook Harsha Engineers International Ltd. has delivered a strong set of Q2 results, prompting IDBI Capital to upgrade the stock to ‘Buy’ with a potential upside of 20%. The company’s revenue grew by 7% year-over-year (YoY), while Ebitda surged by 28% YoY to Rs
Introduction to the Indian and Chinese Markets The Indian and Chinese stock markets have been making headlines in recent times, with China experiencing a resurgence in its stock market, while India has been underperforming. According to Mark Matthews, Head of Research Asia at Julius Baer, these two markets are driven by different fundamentals and opportunities,
Indigo Paints Q2 Review: A Detailed Analysis Indigo Paints Ltd. has reported a strong Q2 performance, with revenue growth of 4.2% YoY, outperforming its key peers Kansai Nerolac, Berger Paints, and Akzo Nobel. The company’s Ebitda margin expansion of +106bps is also a notable achievement, especially when compared to the margin contractions seen by Berger
Lenskart IPO: Ambit Gives Sell Rating, Cites Valuation Concerns Lenskart, the popular eyewear retailer, is set to list on the Indian stock markets on Monday, but has already received its first sell rating from Ambit, a leading brokerage firm. The rating comes as a surprise, given Lenskart’s strong brand and growth prospects. However, Ambit believes
Hindalco Q2 Results: Strong Performance by India Business Drives 21% Profit Rise Aditya Birla Group’s metals arm Hindalco Industries Ltd has reported a 21.2% rise in consolidated profit after tax at Rs 4,741 crore in the quarter ended September 2025. This significant increase can be attributed to the strong performance by the India business, disciplined
Indoco Remedies Q2 Review: A Mixed Bag for Investors Indoco Remedies Ltd., a leading Indian pharmaceutical company, recently announced its Q2 FY26 earnings, which came in above estimates. However, despite the positive earnings surprise, Dolat Capital has downgraded its Ebitda estimates and maintained a ‘Sell’ rating with a revised target price of Rs 224. Q2
Nifty Consolidates Ahead of Major Earnings The Indian stock market witnessed a volatile session today, with the NSE Nifty 50 rebounding from its day’s lows to hold the 25,500 level, while the BSE Sensex slipped nearly 100 points. The Nifty Metal index emerged as the top-performing sector, while the Nifty IT index became the worst-performing
P&G Hygiene and Healthcare Ltd. Q2 Review: Key Highlights and Takeaways P&G Hygiene and Healthcare Ltd., a leading player in the Indian hygiene and healthcare sector, recently announced its Q2 results. The company’s performance was marred by weak gross margins, which had a significant impact on its profitability. In this article, we will delve into
Nykaa Q2 Results: A Comprehensive Analysis FSN E-Commerce Ventures Ltd., commonly known as Nykaa, has released its Q2 results for FY26, and the numbers are impressive. The company has reported a net profit of Rs 34.4 crore, which is a threefold increase from the Rs 10 crore reported in the year-ago period. Revenue has also